Click Therapeutics

Click Therapeutics and Boehringer Ingelheim partner to develop and market a digital therapeutic to treat schizophrenia

by

Boehringer Ingel­heim, Click Ther­a­peu­tics ink $500M+ dig­i­tal ther­a­peu­tics devel­op­ment, com­mer­cial­iza­tion deal (Mobi­Health­News):

Inter­na­tion­al phar­ma Boehringer Ingel­heim and pre­scrip­tion dig­i­tal ther­a­peu­tics com­pa­ny Click Ther­a­peu­tics have inked a $500 mil­lion-plus deal to joint­ly devel­op and com­mer­cial­ize a dig­i­tal treat­ment for patients with schiz­o­phre­nia. [Read more…] about Click Ther­a­peu­tics and Boehringer Ingel­heim part­ner to devel­op and mar­ket a dig­i­tal ther­a­peu­tic to treat schizophrenia

Trend: Pharma industry warming up to digital therapeutics

by

– Som­ryst app by Pear Therapeutics

Dig­i­tal ther­a­peu­tics have poten­tial but com­mer­cial suc­cess unproven (Van­tage):

“Devel­op­ing drugs to treat dis­or­ders of the cen­tral ner­vous sys­tem is famous­ly fraught with dif­fi­cul­ty. Sev­er­al com­pa­nies, includ­ing Pear Ther­a­peu­tics and Dthera, are tak­ing a wild­ly dif­fer­ent approach: dig­i­tal ther­a­peu­tics. These are pieces of soft­ware designed to treat dis­ease that are reg­u­lat­ed, pre­scribed and even paid for as if they were drugs … Pear is so far the only com­pa­ny to have brought a dig­i­tal ther­a­peu­tic to mar­ket – but it is by no means the only com­pa­ny in this space. Akili Inter­ac­tive has­filed for FDA approval of AKL-T01, a com­put­er game designed to treat ADHD, and [Read more…] about Trend: Phar­ma indus­try warm­ing up to dig­i­tal therapeutics

How to intervene early to address brain/ mental health problems: Examples in depression, epilepsy and smoking cessation

by

We hope you enjoy this slid­edeck sup­port­ing a fas­ci­nat­ing, for­ward-look­ing ses­sion held at the 2019 Sharp­Brains Vir­tu­al Sum­mit: The Future of Brain Health (March 7–9th).  Full record­ings are avail­able for pur­chase here.

10.45am-12.15pm. How to inter­vene ear­ly: Exam­ples in depres­sion, epilep­sy and smok­ing cessation 

  • Dr. Wal­ter Green­leaf, Research Sci­en­tist at Stan­ford University’s Vir­tu­al Human Inter­ac­tion Lab
  • David B. Klein, CEO of Click Ther­a­peu­tics
  • Ana Maiques, CEO of Neu­ro­electrics
  • Chaired by: Avery Bedows, Neu­rotech­nol­o­gy Spe­cial­ist at Loup Ven­tures

10+ pioneers confirmed to Speak @ 2019 SharpBrains Virtual Summit (May 7–9th)

by

_______________

We are proud to announce the first wave of con­firmed Speak­ers to share their inno­v­a­tive work and insights at the 2019 Sharp­Brains Vir­tu­al Sum­mit: The Future of Brain Health, to be held May 7–9th, 2019:

Dr. Tom Insel, Co-founder and Pres­i­dent of Mind­strong Health
Dr. Ainslie Hatch, Direc­tor of Dig­i­tal Ther­a­peu­tics at Otsu­ka Pharmaceutical
David Klein, CEO of Click Ther­a­peu­tics
Char­lie Hartwell, Oper­at­ing Part­ner at The Bridge Builders Collaborative
Louis Gagnon, CEO of Total Brain
Dr. Anna Wexler, sci­ence writer and PI of the Wexler Lab at UPenn
Dr. Eddie Mar­tuc­ci, Founder and CEO of Akili Inter­ac­tive Labs
Ana Maiques, CEO of Neu­ro­electrics
Jan Samzelius, Founder and CEO of Neu­raMetrix
Dr. Peter White­house, Pro­fes­sor of Neu­rol­o­gy at Case West­ern Reserve University
Kito Toset­ti, CEO of CTF MEG International
Ariel Garten, Founder and Chief Evan­ge­lism Offi­cer of Inter­aX­on
Alvaro Fer­nan­dez, CEO and Edi­tor-in-Chief of Sharp­Brains

We can’t wait to discuss and help shape the Future of Brain Health!

_______________

Imag­ine your smart­phone can detect ear­ly signs of anx­i­ety, depres­sion or Parkinson’s Dis­ease — would you like to know? Who else should know … and not know?

Imag­ine a videogame cleared by the FDA to treat ADHD or sub­stance abuse — how will doc­tors pre­scribe it, patients access it, and insur­ers pay for it?

Imag­ine being respon­si­ble for the health & well­ness of your orga­ni­za­tion — how will you nav­i­gate the grow­ing toolk­it of evi­dence-based inter­ven­tions such as exercise/ meditation/ sleep apps/ cog­ni­tive therapies/ biofeedback/ tDCS?

Imag­ine invest­ing $100 mil­lion to help accel­er­ate brain research and appli­ca­tions — how would you ensure that respon­si­ble devel­op­ment meets wise adop­tion?

Imag­ine a free annu­al brain check-up — who should take it, and how could it help prevent/ delay/ treat cog­ni­tive decline and Alzheimer’s Disease?

_______________

LEARN MORE HERE

Otsuka Pharma and Click Therapeutics enter partnership poised to transform mental healthcare

by

Otsu­ka, Click Ther­a­peu­tics part­ner to cre­ate ther­a­py for men­tal ill­ness (Ver­dict Med­ical Devices):

“Otsu­ka Pharmaceutical’s US divi­sion Otsu­ka Amer­i­ca has part­nered with Click Ther­a­peu­tics to devel­op and com­mer­cialise a pre­scrip­tion dig­i­tal ther­a­peu­tic for treat­ing major depres­sive dis­or­der (MDD) [Read more…] about Otsu­ka Phar­ma and Click Ther­a­peu­tics enter part­ner­ship poised to trans­form men­tal healthcare

Sanofi Ventures leads $17M investment in Click Therapeutics, finalist @ 2017 Brainnovations Pitch Contest

by

Sanofi Backs Click Ther­a­peu­tics as Dig­i­tal Med­i­cines Gain Momen­tum (Xcon­o­my):

“Drug mak­ers are mak­ing more bets on the nascent field of dig­i­tal med­i­cine. The lat­est exam­ple: Click Ther­a­peu­tics announced Mon­day that it grabbed a $17 mil­lion invest­ment led by Sanofi Ven­tures, the Cam­bridge, MA-based ven­ture cap­i­tal arm of the French phar­ma­ceu­ti­cal giant. [Read more…] about Sanofi Ven­tures leads $17M invest­ment in Click Ther­a­peu­tics, final­ist @ 2017 Brain­no­va­tions Pitch Contest